Skip to content
OpenCapital
Get started

Viridian Therapeutics, Inc. VRDN Accrued outsourced clinical and nonclinical studies

Other financials

Income statement

See full
Revenue$141.0K+95.8%
Operating income-$116.2M-23.8%
Net income-$104.9M-20.7%
EPS (diluted)-$1.15-5.5%

Balance sheet

See full
Cash & equivalents$176.3M+51.7%
Total debt$36.8M+59.4%
Total equity$636.0M+5.2%
Total assets$789.0M+19.4%

Cash flow

See full
Operating cash flow-$119.7M-29.1%
CapEx$23.0K-73.3%
Free cash flow-$119.7M-29.0%

Valuation

See full
Market cap$1.91B+82.0%

Profitability

See full
Gross margin36.3%—
Operating margin-543.9%-271pp
Net margin-508.5%-254pp
FCF margin-428.4%-214pp

Returns & leverage

See full
Return on equity-58.1%+7.9pp
Debt / equity0.1×0.0×
Current ratio15.1×-4.3×

Where this comes from

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept vrdn:AccruedOutsourcedClinicalAndNonclinicalStudiesCurrent.

The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Viridian Therapeutics, Inc.'s accrued outsourced clinical and nonclinical studies?
Viridian Therapeutics, Inc. (VRDN) reported accrued outsourced clinical and nonclinical studies of $5.92M in Q1 2026.